New drug combo shows promise for Tough-to-Treat Ewing's sarcoma
NCT ID NCT05046314
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a new drug called TK216 combined with the chemotherapy drug vincristine in 15 people with Ewing's sarcoma that had come back or stopped responding to treatment. The main goal was to see how many patients' tumors shrank or disappeared. The study was completed in China and aimed to find a better option for this rare cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TK216 (a drug) combined with vincristine (a chemotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for people with Ewing's sarcoma that has come back or not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug combination may cause side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, EWING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University Cancer Institude & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 100005, China